Thu, Mar 5, 2015, 6:09 AM EST - U.S. Markets open in 3 hrs 21 mins


% | $
Quotes you view appear here for quick access.

Amarantus Bioscience Holdings, Inc Message Board

  • nidan7500 nidan7500 Jun 22, 2014 8:18 AM Flag better be...

    "The LymPro Test® is the Company's flagship blood test for Alzheimer's disease. LymPro was designed with the purpose of diagnosing Alzheimer’s in its mild to moderate stage. This patient-specific identification has the potential to become an invaluable tool for Alzheimer’s disease clinical trials, where there has been a well-documented history of patient recruitment errors related to inaccurate diagnosis of Alzheimer’s"

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This, ladies and gentlemen is hardball...all the best.

      "The Company has had 3 posters accepted for presentation (analytical performance, LP001 retrospective 7 year patient record clinical performance data, and LP002 2014 clinical performance) at the Alzheimer’s Association International Conference (AAIC) this July in Copenhagen under the direction of Dr. Louis Kirby and Paul Jorgensen. Our primary focus will be the data of the LP001 retrospective patient record study currently underway with our collaborator’s facility at Banner Sun Health Research Institute in Phoenix, AZ. We believe this data will be the most compelling for Key Opinion Leaders (KOLs) and pharmaceutical companies, our target market for the initial launch of LymPro, as this will provide longitudinal data regarding LymPro’s performance and diagnostic integrity.

      The Company is contemplating withholding the release of the LP002 clinical performance data until our #C4CT Concussion Awareness Summit, which will focus on TBI-induced Alzheimer’s disease, at the United Nations on July 31st. This would allow the Company to maintain a laser focus on potential customers at AAIC using the most compelling LP001 retrospective data and allowing the information to be thoroughly digested by the scientific community and analysts. In doing so, the LP002 data would be shared with family offices and a world-expert panel of TBI and Alzheimer’s researchers who would then be in a position to sign on as sites for the validation study required for CLIA registration. We will update the market on this option in the weeks ahead. - "

0.0805-0.0025(-3.01%)Mar 4 3:59 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.